AN independent review of the
cost recovery arrangements for
Pharmaceutical Benefit Scheme
submissions has found that the
revenue from the program is
“significantly lower than
anticipated when the measure was
introduced”.
A committee was established in
Jul last year to look at the impact
cost recovery has had on the PBS,
and while concluding that overall
there is insufficient data available
to ascertain the impact, also
recommended that the costing
model be reevaluated “to ensure
that all costs associated with the
evaluation and listing processes are
included”.
The report, now available online
at www.pbs.gov.au, also noted a
number of fee exemptions and
waivers, and that about a third of
sponsors predicted an estimated
annual use of less than 2000 scripts
in the first 12 months of listing.The above article was sent to subscribers in Pharmacy Daily's issue from 21 Sep 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Sep 12
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.